A recent clinical trial has revealed promising results for the use of the immunotherapy drug dostarlimab in treating early-stage cancers with mismatch repair deficiency (dMMR). Published in The New England Journal of Medicine, the study involved 117 patients diagnosed with dMMR solid tumors, primarily colorectal cancer. Participants underwent six months of treatment with dostarlimab, receiving nine doses over that period.
The findings indicated that 80% of the patients did not require surgery, chemotherapy, or radiation therapy following treatment. Specifically, all 49 patients with colorectal cancer experienced complete remission, allowing them to avoid surgical intervention. The results suggest that immunotherapy could significantly enhance patients' quality of life by preserving organs and reducing the harsh side effects typically associated with conventional cancer treatments.
Lead author Dr. Andrea Cercek emphasized the significance of these results, noting that the ability to eliminate cancer without surgery is a major advancement in cancer treatment. The study found that 92% of patients remained cancer-free two years post-treatment. Most reported only mild side effects, such as fatigue or rash, with some patients showing no detectable cancer within one to two months after starting treatment.
Expert opinions highlight the transformative potential of these findings. Dr. Steven Quay, a physician-scientist not involved in the study, described the research as a paradigm shift in cancer treatment, suggesting that it may change how clinicians approach solid tumors. He noted that the focus is shifting from surgical removal to leveraging the immune system to combat cancer.
Overall, dostarlimab represents a significant advancement for patients with dMMR tumors, offering a novel therapeutic pathway that could redefine standard treatment practices in oncology.